CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer

被引：1
|
作者：
Conley, Sarah J. [1 ]
Baker, Trenton L. [1 ]
Burnet, Joseph P. [1 ]
Thiesen, Rebecca L. [1 ]
Lazarus, Douglas [2 ]
Peters, Christian G. [2 ]
Clouthier, Shawn G. [1 ]
Eliasol, Scott [2 ]
Wicha, Max S. [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[2] Cerulean Pharma Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1384
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1384
引用
收藏
页数：1
相关论文
共 16 条
  • [1] Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
    Elizabeth Pham
    Yin, Melissa
    Peters, Christian G.
    Lee, Christina R.
    Brown, Donna
    Xu, Ping
    Man, Shan
    Jayaraman, Lata
    Rohde, Ellen
    Chow, Annabelle
    Lazarus, Douglas
    Eliasof, Scott
    Foster, F. Stuart
    Kerbel, Robert S.
    CANCER RESEARCH, 2016, 76 (15) : 4493 - 4503
  • [2] CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
    Sarah J. Conley
    Trenton L. Baker
    Joseph P. Burnett
    Rebecca L. Theisen
    Douglas Lazarus
    Christian G. Peters
    Shawn G. Clouthier
    Scott Eliasof
    Max S. Wicha
    Breast Cancer Research and Treatment, 2015, 150 : 559 - 567
  • [3] CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
    Conley, Sarah J.
    Baker, Trenton L.
    Burnett, Joseph P.
    Theisen, Rebecca L.
    Lazarus, Douglas
    Peters, Christian G.
    Clouthier, Shawn G.
    Eliasof, Scott
    Wicha, Max S.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (03) : 559 - 567
  • [4] Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload
    Tian, Xi
    Minh Nguyen
    Foote, Henry
    Wagner, Kyle T.
    Sanoff, Hanna K.
    McRee, Autumn J.
    O'Neil, Bert H.
    Calvo, Benjamin F.
    Blackstock, William A.
    Tepper, Joel E.
    Garmey, Edward
    Eliasof, Scott
    Wang, Andrew Z.
    CANCER RESEARCH, 2015, 75
  • [5] Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1α
    Pham, Elizabeth
    Lee, Christina R.
    Xu, Pin
    Man, Shan
    Yin, Melissa
    Foster, F. Stuart
    Peters, Christian G.
    Lazarus, Douglas
    Eliasof, Scott
    Kerbei, Robert S.
    CANCER RESEARCH, 2015, 75
  • [6] Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis
    Lin, Chien-Ju
    Lin, Yi-Ling
    Luh, Frank
    Yen, Yun
    Chen, Ruei-Ming
    ONCOTARGET, 2016, 7 (27) : 42408 - 42421
  • [7] CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index
    O'Connor, Lenka Oplustil
    Wang, Anderson T.
    Jones, David
    Odedra, Rajesh
    Spreadborough, Michael
    Wilson, Joanne
    Smith, Aaron
    Cotton, Peter
    Reens, Jaimini
    Barnes, Jen
    Sheridan, Victoria
    Tellez, Andres
    Lau, Alan
    Sadler, Claire
    O'Connor, Mark J.
    Eliasof, Scott
    MOLECULAR CANCER RESEARCH, 2017, 15
  • [8] CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
    Tian, Xi
    Minh Nguyen
    Foote, Henry P.
    Caster, Joseph M.
    Roche, Kyle C.
    Peters, Christian G.
    Wu, Pauline
    Jayaraman, Lata
    Garmey, Edward G.
    Tepper, Joel E.
    Eliasof, Scott
    Wang, Andrew Z.
    CANCER RESEARCH, 2017, 77 (01) : 112 - 122
  • [9] CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α (vol 77, pg 112, 2017)
    Tian, X.
    Nguyen, M.
    Foote, H. P.
    Caster, J. M.
    Roche, K. C.
    Peters, C. G.
    CANCER RESEARCH, 2017, 77 (23) : 6790 - 6791
  • [10] Preclinical activity of new investigational drug ONC201 in triple-negative and non-triple negative and BRCA1-deficient breast cancer cells.
    Baumeister, Marie D.
    Wagner, Jessica
    Prabhu, Varun V.
    Kline, Christina Leah B.
    Allen, Joshua E.
    Dicker, David T.
    El-Deiry, Wafik S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12